Background: Inherited thrombocytopenias (ITs) are a heterogeneous group of disor-
| INTRODUCTION
Inherited thrombocytopenias (ITs) are a heterogeneous group of disorders characterized by a sustained reduction in platelet count often manifesting as a bleeding diathesis. Since the discovery of disease inheritance patterns in disorders such as Bernard Soulier Syndrome (BSS), genetic studies of thrombocytopenia have been a vital tool in determining megakaryocyte and platelet physiology. 1 As a result of parallel whole exome and whole genome sequencing over the past 5-10 years, we are discovering increasing numbers of novel genes and variants with a critical role in platelet production, physiology, and function. [2] [3] [4] [5] To date, there are 30 genes suspected to cause 26 separate forms of inherited thrombocytopenia making genetic diagnosis complex. 6 However, until recently, IT remained underdiagnosed with previous studies only providing a genetic diagnosis in just over 50%
of individuals. [7] [8] [9] A genetic diagnosis provides clinical benefits for the patients. Some patients with a reduced platelet count have had unnecessary treatments and procedures such as immunosuppression and splenectomies and therefore establishing that they have an inherited component to their disease etiology would prevent this. In the case of suspected ITP this may be treated with steroids or immunosuppressive drugs with many side effects. Therefore, if such patients are proven to have an inherited thrombocytopenia, then these treatments are unnecessary. Some of the gene mutations in patients, eg, RUNX1, result in patients having a predisposition to hematological malignancies and once a genetic defect is proven, the information can be used to monitor the patients' hematological parameters more closely. These all highlight the need for a definitive genetic diagnosis and development of a targeted gene-specific sequencing platform will provide a quick and cost effective screening for patients with IT.
As new sequencing library-capture methods are developed, the speed of sample preparation time is vastly reduced. Thus, the recently released capture methods, Illumina Nextera Rapid Custom
Methods:
We have developed an IT-specific gene panel as a pre-screen for patients prior to WES using the Agilent SureSelect QXT transposon-based enrichment system.
Results:
Thirty-one patients were analyzed using the panel-based sequencing, of which; 10% (3/31) were identified with a classified pathogenic variant, 16% (5/31) were identified with a likely pathogenic variant, 51% (16/31) were identified with variants of unknown significance, and 23% (7/31) were identified with either no variant or a benign variant.
Discussion and Conclusion:
Although requiring further clarification of the impact of the genetic variations, the application of an IT-specific next generation sequencing panel is a viable method of pre-screening patients for variants in known IT-causing genes prior to WES. With an added benefit of distinguishing IT from idiopathic thrombocytopenic purpura (ITP) and the potential to identify variants in genes known to have a predisposition to hematological malignancies, it could become a critical step in improving patient clinical management.
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Essentials
• Inherited thrombocytopenias are a heterogeneous group of disorders with over 30 causative genes identified to date.
• We have developed an IT-specific gene panel to screen patients using the rapid Agilent SureSelect QXT transposon-based enrichment system.
• Candidate gene variants were observed in previously implicated IT genes in 77% of individuals; 10% of patients had a classified pathogenic variant, 16% had a likely pathogenic variant, 51% had a variant of unknown significance and 23% had no or a benign variant.
• Accurate genetic diagnosis could improve the clinical outcome for this group of patients with disproportionate bleeding for their reduced platelet count.
Capture Enrichment and Agilent SureSelect QXT , both propose an improvement in sample preparation without limitations in sequence depth, coverage, and accuracy. 10 When applied to small-scale custom gene panels, the preparation time can be reduced to one day. In addition, DNA input is also reduced allowing for amplification from <50 ng of DNA. 
| ME THODS

| Patients
Patients were recruited from participating UK hematology centers.
All patients had a bleeding history taken at the point of examination and inclusion into the study. Most patients suffered from mild bleeding symptoms including cutaneous bruising, bleeding, and epistaxis in addition to more severe bleeding symptoms in some cases. Detailed patient clinical symptoms related to bleeding that were available are displayed in Table 1 .
The UK-GAPP study was approved by the National Research Ethics 
| Platelet counts and morphology
Platelet counts and morphology were measured from patients in whole blood using the Sysmex XN-1000 (n = 31). The PLT-F channel was used to determine platelet counts in whole blood and the immature platelet fraction (IPF). Mean platelet volume (MPV) was determined from the impedance PLT-I channel. All samples were processed in tandem with travel controls.
| Platelet preparation and platelet function testing
This study focuses on a subset of patients with a reduction in platelet count. Previous studies by the UK-GAPP study group have demonstrated the applicability of using light transmission aggregometry (LTA), including lumiaggregometry, for investigation of PRP samples having platelet counts exceeding 1 × 10 8 /mL 13 Eighteen genes were covered entirely using the highest stringency setting, eight genes were covered by a combination of high and moderate stringency settings, and the remaining four genes were covered by baits using a combination of all three stringency settings.
Balanced boosting of GC-rich probes was used which replicated the amount of probes within a GC-rich region by a defined factor to improve capture of these difficult genomic fragments. A maximum of 16 samples were prepared per run. DNA samples were quantified using BR and High Sensitivity (HS) Qubit dsDNA fluorometric quantification kits and were analyzed using a Qubit 2.0 Fluorimeter (ThermoFisher, UK, #Q32854 for HS kit) in initial sample preparation. Purification steps utilized Agencourt AMPure XP magnetic capture beads (BeckmanCoulter, UK, #A63880). DNA quantity and quality was assessed at two separate points throughout the protocol using an Agilent 2200 Tapestation system and associated D1000 and high sensitivity D1000 screen tape (#5067-5582 for D1000, #5067-5584 for HS D1000), and reagents (including ladder and sample buffers) (#5067-5583 for D1000 reagents, #5067-5585 for HS D1000 reagents) (Agilent Technologies).
Dynabeads MyOne Streptavidin T1 magnetic beads were used for hybrid capture (ThermoFisher, #65601). Index tags were added using the SureSelect QXT P7 and P5 dual indexing primers. All thermocycling steps were performed using a Bio-Rad DNA Engine
Tetrad 2 Thermal Cycler (Bio-Rad, UK). Magnetic separation was achieved using a DynaMag-96 Side magnet (ThermoFisher).
Samples were then pooled for multiplexed sequencing so that each index-tagged sample was in equimolar amounts in the pool. Finally sequencing was performed using an Illumina MiSeq (Illumina, UK) and MiSeq v2 300 Cycle Reagent Kits (Illumina, #15033626). Sample sheets were designed to allow for the use of custom primers and no adaptor trimming. Sequencing followed a Nextera XT sample preparation kit and amplicon chemistry.
Sequence alignment, annotation, categorisation and variant calling was performed using the SureCall v3.5 software (Agilent Technologies) and the GenAligners 3.0 alignment tool (Agilent Technologies). Post aligned, annotated, and categorized sequence data was analyzed using a personalized bioinformatics pipeline as discussed below.
| Bioinformatics pipeline to determine candidate variants
Sequence data generated using the IT-specific NGS panel was analyzed using an adaptation of the pipeline developed for the analysis of WES data. 12 Variants were initially filtered on frequency, excluding variants with a MAF ≤0.01 in the 1000-G database. Synonymous variants not predicted to change the amino acid sequence in the protein coding transcripts were then excluded. As the panel was designed to include the 5′ and 3′ UTRs, variants were additionally /L, n = 40). Average MPV = 11.1 fL (mean normal range to 2 SD 7.8-12.69 fL, n = 40). IPF was available for 20 patients and varied between 1.8-59.4% (normal range 1.3-10.8%, n = 40). Patients with an observed macro and micro thrombocytopenia are denoted by a + and -, respectively, following their most recent analyzed MPV. Secondary qualitative defects are abbreviated to the following; (CD41) reduction in the resting cell surface levels of CD41, (CD42b) reduction in resting cell surface levels of CD42b, (ADP) reduction in response upon ADP stimulation indicating a possible defect in the Gi pathway, (AA) reduction (cyclooxygenase pathway defect), (Adr) reduction (Thromboxane receptor pathway defect), (GPVI) reduction in surface GPVI quantity, (P-selectin) reduction (platelet alpha-granule/secretion defect), (fibrinogen) reduction in the binding of fibrinogen to activated platelets, (ATP secretion) reduction in ATP secretion upon stimulation with PAR-1 peptide 100 μmol/L. Bleeding diathesis of each individual is summarized under bleeding phenotype. AA, arachadonic acid; ADP, Adenosine diphosphate; Adr, adrenaline; ATP, Adenosine triphosphate; GPVI, Glycoprotein VI; IPF, immature platelet fraction; LTA, light transmission aggregometry; MPV, mean platelet volume. + denotes an elevated MPV/IPF; NA indicates parameter was tested but results were inconclusive; NT indicates parameter was not tested due to degraded or limited sample; UNK indicates the parameter was not known.
TA B L E 1 (Continued) filtered dependent on their genomic location within the coding region ±10 bp of intron-exon boundaries. The UTRs were included in bait design to allow detection of variants within the 5′ UTR of ANKRD26 so that all variants occurring within the 5′UTR of genes were analyzed individually. Candidate variants identified were scrutinized using the same in silico pathogenicity prediction software and variant classification system as candidates from WES analysis as outlined previously. 12 Finally, pathogenicity of variants was determined and called using the consensus guidelines as set out by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (hence forth referred to as the ACMG guidelines). 
| Validation of IT-specific NGS panel
Validation of the IT-specific NGS panel was performed by analyzing the panel's sensitivity in detecting eight variants identified previously by WES analysis and confirmed by Sanger sequencing. Variants, at the time of validation, were likely candidate variants and include variants in genes not known previously to cause IT (see Table 2 ). All variants, excluding a previously identified frameshift causing insertion in TUBB1;
c.1080_1081insG, p.Leu361Alafs*19 previously identified using WES in patient 31, 12 were successfully identified, presumably due to the sequence context around this genomic region.
All known candidate variants tested were the only candidate variants following bioinformatics analysis of panel sequencing results in each patient.
| Candidate variants observed and variant prevalence in 31 new patients
In total, DNA samples from 31 new patients were analyzed by an IT-specific NGS panel. All patients, with the exception of 64, were single affected cases. Patient 64 forms part of a pedigree of four affected family members which will be discussed in more detail in the discussion section. Following post-sequencing bioinformatics analysis candidate variants previously implicated in IT genes were observed in 77% of individuals (Table 3 Of the 37 variants, 11 (30%) were novel and not previously identified in any of the databases scrutinized. Twenty-six variants have been observed previously and the prevalence of these variants in the ExAC database, unless otherwise stated, is displayed in Table 3 .
When comparing all previously observed variants an average MAF of 0.00256 is noted. All variants were observed at a frequency of less than 0.01 and all previously identified variants, with the exception of rs111527738 which was present within the latest build of dbSNP. Four pathogenic or likely pathogenic variants were identified that are previously known to cause IT. These were found in pa- 
| Conservation, pathogenicity prediction, and variant classification
Conservation at the site of variation was determined by PhyloP and PhastCons in silico software. Conservation scores for all variants occurring within known IT-causing genes in the 31 patients are shown in Table 3 . Average scores of 3.32887 and 0.829571
were observed across all variants in PhyloP and PhastCon analysis, respectively. The majority of variants occurred at sites of high conservation and the two methodologies used were in agreement in all instances.
Pathogenicity was predicted using in silico prediction software as displayed in Table 3 . Classification often varied amongst the software used for each variant indicating the benign potential of the variants observed.
In total, of the 37 total variants noted across all patients investigated, three variants were classified as "pathogenic" and five "likely 
| DISCUSSION
An IT gene-specific NGS panel was developed in order to pre-screen patients prior to WES. The aim was to filter out patients with variants in known IT-causing genes allowing subsequent focus on WES for patients who may harbor variants in novel genes. In addition, the cost implications were an important consideration given that the WES was more than four times as expensive compared with targeted panel sequencing.
All sequencing passed QC at all points throughout sample preparation and QC, cluster density and overall sequencing data was sufficient when compared with routine sequencing using al- and an average read depth of 380 was identified at the points of variation. 19 With a GC content of 73%, GP1BB often suffers from a reduction in coverage, which is why in WES analysis the gene was manually Comparing pathogenicity prediction and variant classification to the variants determined by WES analysis, a larger percentage of variants were deemed to be of unknown significance. This may reflect a reduced rate of sensitivity and a higher proportion of false negative variants identified. However, it is worth considering that the majority of variants, 62% (23 of 37), displayed supporting evidence of pathogenicity but lacked sufficient evidence to be classified as such.
This could potentially be an indication of the lack of strengthening evidence that is normally provided in the form of related affected family members that would be recruited to the study, negatively affecting classification because of a lack of segregation analysis.
The presence of a variant in MYH9 in patient 64 highlights the difficulty of picking up such defects despite the routine pre-screening for disorders such as BSS-and MYH9-related disease (using flow cytometry or the presence of granulocyte inclusions, respectively) in hemophilia care centers before recruitment to the UK-GAPP study. This was also the case in our previous study where we employed WES and detected MYH9
and BSS defects despite pre-screening by the referring laboratories. 12 Analyzing patients using the IT-specific panel has elucidated variants in genes known to cause BSS-and MYH9-related Interestingly a reduction in cell surface expression of CD42b, encoded by GP1BA, was noted in patient 50, who harbors a potentially deleterious large deletion of GP1BB that spans two previously reported disease-causing variants. 23, 24 Although not occurring in the encoded gene, the variant, due to the detrimental effect of a frameshift causing deletion, may have propensity to disrupt the stability of the receptor complex leading to a reduction in cell surface expression.
As with variants determined by WES analysis, the variants observed following the application of the IT-specific NGS panel require further conformational work to be determined disease causing.
Further work would focus around this point mainly, utilizing many of the biomarkers of disease attributed to variants in certain genes and recruiting related affected family members of previously analyzed patients. This will strengthen any initial genetic variants that may be indicative of disease through segregation analysis but it also has the propensity to spread disease awareness of an under recognized and under-diagnosed genetic disorder. 
